DexCom, Inc. (DXCM)
NASDAQ: DXCM · Real-Time Price · USD
80.00
-1.01 (-1.25%)
At close: Jun 20, 2025, 4:00 PM
80.01
+0.01 (0.01%)
After-hours: Jun 20, 2025, 7:43 PM EDT
DexCom Revenue
DexCom had revenue of $1.04B in the quarter ending March 31, 2025, with 12.49% growth. This brings the company's revenue in the last twelve months to $4.15B, up 9.11% year-over-year. In the year 2024, DexCom had annual revenue of $4.03B with 11.34% growth.
Revenue (ttm)
$4.15B
Revenue Growth
+9.11%
P/S Ratio
7.60
Revenue / Employee
$402,718
Employees
10,300
Market Cap
31.37B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 4.03B | 410.70M | 11.34% |
Dec 31, 2023 | 3.62B | 712.50M | 24.49% |
Dec 31, 2022 | 2.91B | 461.30M | 18.84% |
Dec 31, 2021 | 2.45B | 521.80M | 27.08% |
Dec 31, 2020 | 1.93B | 450.70M | 30.54% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
DXCM News
- 2 days ago - Dexcom Unveils New Report on Type 2 Diabetes Management in the U.S. at ADA 2025 - Business Wire
- 10 days ago - Johnson Fistel Continues Investigation on Behalf of DexCom, Inc. Shareholders - Business Wire
- 16 days ago - Jefferies' high conviction US stocks for the summer: Nvidia among top picks - Invezz
- 5 weeks ago - Dexcom Announces Promotion of Jake Leach to the Expanded Role of President and COO - Business Wire
- 6 weeks ago - DexCom Q1 Earnings: Organic Revenue Growth Versus Cost Pressure - Seeking Alpha
- 6 weeks ago - DexCom: Growth Is Reaccelerating But Don't Ignore The Risks - Seeking Alpha
- 7 weeks ago - Nasdaq Index: Dexcom, Meta, ON Semi Lead US Stocks Rebound on Trade Optimism - FXEmpire
- 7 weeks ago - Dexcom Stock Is Today's Big Winner After Earnings. Why the Medtech Is Soaring. - Barrons